» Articles » PMID: 28558984

Human Immune Responses Against Shigella and Enterotoxigenic E. Coli: Current Advances and the Path Forward

Overview
Journal Vaccine
Date 2017 Jun 1
PMID 28558984
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Robust and well-established immunological assays and firm immune correlates of protection that can predict disease outcome and/or vaccine efficacy are essential to adequately assess human immune responses to infection and vaccination. The availability of reagents and calibrated controls is also critically important to standardize assays and generate comparable results among different laboratories. The workshop "Human Immune Responses against Shigella and ETEC: Current Advances and the Path Forward" held during the VASE meeting provided an opportunity to disseminate and discuss recent advances in the field of Shigella and ETEC immunology, identify research needs, and propose collaborative activities to advance the field. Four presentations featured current knowledge on humoral and cellular immune responses to Shigella and ETEC during infection and vaccination. A discussion followed on immunological methods relevant for clinical studies, immune parameters associated with protection, harmonization of assays among laboratories, and availability of reagents and standards. Specific recommendations proposed to facilitate "the path forward" included supporting communication among scientists, harmonization of assays and sharing of protocols, the creation of a repository of reagents and calibrated controls and distribution of such material to the research community, and expansion of exploratory studies to better understand the interactions between these pathogens and the human immune system and the ensuing responses.

Citing Articles

Proportions of IgA antibodies targeting glycosylated epitopes of secreted Escherichia coli mucinase YghJ in initial plasmablast response differ from salivary and intestinally secreted IgA.

Riaz S, Steinsland H, Andersen A, Boysen A, Hanevik K Med Microbiol Immunol. 2024; 214(1):2.

PMID: 39673573 PMC: 11646272. DOI: 10.1007/s00430-024-00812-0.


Ascorbate deficiency increases progression of shigellosis in guinea pigs and mice infection models.

Skerniskyte J, Mulet C, Andre A, Anderson M, Injarabian L, Buck A Gut Microbes. 2023; 15(2):2271597.

PMID: 37876025 PMC: 10730169. DOI: 10.1080/19490976.2023.2271597.


Functional assays to evaluate antibody-mediated responses against : a review.

Boero E, Vezzani G, Micoli F, Pizza M, Rossi O Front Cell Infect Microbiol. 2023; 13:1171213.

PMID: 37260708 PMC: 10227456. DOI: 10.3389/fcimb.2023.1171213.


Sensitivity and predictive value of dysentery in diagnosing shigellosis among under five children in Zambia.

Miti S, Chilyabanyama O, Chisenga C, Chibuye M, Bosomprah S, Mumba C PLoS One. 2023; 18(2):e0279012.

PMID: 36827347 PMC: 9955635. DOI: 10.1371/journal.pone.0279012.


Molecular mechanisms of Shigella effector proteins: a common pathogen among diarrheic pediatric population.

Nasser A, Mosadegh M, Azimi T, Shariati A Mol Cell Pediatr. 2022; 9(1):12.

PMID: 35718793 PMC: 9207015. DOI: 10.1186/s40348-022-00145-z.


References
1.
Lin J, Smith M, Benjamin Jr W, Kaminski R, Wenzel H, Nahm M . Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production. Clin Vaccine Immunol. 2016; 23(8):681-8. PMC: 4979179. DOI: 10.1128/CVI.00148-16. View

2.
Behrens R, Cramer J, Jelinek T, Shaw H, von Sonnenburg F, Wilbraham D . Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. Lancet Infect Dis. 2013; 14(3):197-204. DOI: 10.1016/S1473-3099(13)70297-4. View

3.
Cohen D, Green M, Block C, Rouach T, Ofek I . Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis. 1988; 157(5):1068-71. DOI: 10.1093/infdis/157.5.1068. View

4.
Launay O, Sadorge C, Jolly N, Poirier B, Bechet S, van der Vliet D . Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial. Vaccine. 2009; 27(8):1184-91. DOI: 10.1016/j.vaccine.2008.12.021. View

5.
Kotloff K, Herrington D, Hale T, Newland J, Van de Verg L, Cogan J . Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect Immun. 1992; 60(6):2218-24. PMC: 257146. DOI: 10.1128/iai.60.6.2218-2224.1992. View